Potential therapeutic uses for ezetimibe beyond lowering
LDL-c to decrease cardiovascular events
Potential therapeutic uses for ezetimibe beyond lowering
LDL-c to decrease cardiovascular events
Ezetimibe is a relatively new drug that inhibits the absorption of dietary cholesterol in the small intestine. It is an LDL-cholesterol lowering medication that acts directly on the intestine by inhibiting Niemann-Pick C1 Like1 (NPC1L1). Recently, results of the ARBITER 6–HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies) and the ENHANCE trial (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) showed that ezetimibe had no effect on atherosclerosis despite producing a marked decrease in low density lipoprotein cholesterol (LDL-c). Recent studies show a potential benefit of ezetimibe in treating insulin resistance, non-alcoholic fatty liver disease, gallstones and dyslipidaemia associated with chronic renal failure and organ transplantation. All of these conditions are known to be associated with an increase in risk of cardiovascular disease and further studies are needed to assess the potential benefits of ezetimibe in these therapeutics areas.
ezetimibe, non alcoholic fatty liver disease, insulin resistance, gallstones, cardiovascular disease
958-966
Ahmed, M.H.
0dcfcd8b-55bc-48dc-9dbe-24df7fe58269
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
November 2010
Ahmed, M.H.
0dcfcd8b-55bc-48dc-9dbe-24df7fe58269
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Abstract
Ezetimibe is a relatively new drug that inhibits the absorption of dietary cholesterol in the small intestine. It is an LDL-cholesterol lowering medication that acts directly on the intestine by inhibiting Niemann-Pick C1 Like1 (NPC1L1). Recently, results of the ARBITER 6–HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies) and the ENHANCE trial (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) showed that ezetimibe had no effect on atherosclerosis despite producing a marked decrease in low density lipoprotein cholesterol (LDL-c). Recent studies show a potential benefit of ezetimibe in treating insulin resistance, non-alcoholic fatty liver disease, gallstones and dyslipidaemia associated with chronic renal failure and organ transplantation. All of these conditions are known to be associated with an increase in risk of cardiovascular disease and further studies are needed to assess the potential benefits of ezetimibe in these therapeutics areas.
Text
dom_12611.pdf
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Published date: November 2010
Keywords:
ezetimibe, non alcoholic fatty liver disease, insulin resistance, gallstones, cardiovascular disease
Identifiers
Local EPrints ID: 161533
URI: http://eprints.soton.ac.uk/id/eprint/161533
ISSN: 1462-8902
PURE UUID: f7271270-3a6b-4a85-8981-ede00d6297a4
Catalogue record
Date deposited: 30 Jul 2010 15:19
Last modified: 14 Mar 2024 02:43
Export record
Altmetrics
Contributors
Author:
M.H. Ahmed
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
